Access to Care Challenges and Innovation During Covid-19: An Oncology Perspective

October 1, 2020 3:00 PM - 4:00 PM

Webinar, click "live-stream" button to view

Add to Calendar 10/1/2020 3:00:20 PM 10/1/2020 4:00:20 PM Access to Care Challenges and Innovation During Covid-19: An Oncology Perspective

Join us for an informative discussion on how COVID-19 has affected patient access to diagnoses, care, and innovative therapies. We’ve assembled an expert panel that will explore these important issues from an oncology perspective.  Our forum - moderated by Robert K. Coughlin, President & CEO of MassBio - will feature the following speakers:

  • Dr. Meghan Mooradian, MD, Clinical Oncologist, Medical Oncology, Massachusetts General Hospital
  • Kirsten Sloan, Managing Director, Policy, American Cancer Society’s Cancer Action Network (ACS CAN)
  • Michelle Carrillo, Director, Advocacy Relations-Oncology, Amgen


The COVID-19 pandemic has had a profound, direct impact on Massachusetts, with over 121,000 total cases-to-date. However, as response and recovery continue, the ripple effects reveal a much broader public health impact. Our health care system has been shaken to its core, perhaps none more than the area of cancer care.

An American Cancer Society Cancer Action Network (ACS CAN) survey of cancer patients and survivors focused on COVID-19 effects uncovered that of those in active treatment, 79% reported delays to their health care. What does the patient’s path to diagnosis and treatment look like? Has cancer care adapted to meet these challenges? How is Massachusetts uniquely positioned to meet the moment? Our panel of experts will address these questions and more from their patient, oncologist, and innovator perspectives.

MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.



This event is supported by Amgen

 Webinar, click "live-stream" button to view
Clinical Oncologist, Medical Oncology, Massachusetts General Hospital
Dr. Mooradian is a clinical investigator whose main area of interest is the study of the efficacy, toxicity and resistance patterns/mechanisms of immune therapeutics. At the Massachusetts General Hospital (MGH) Cancer Center, she is a member of the Thoracic and Cutaneous Oncology Centers. A key research effort of Dr Mooradian is to better define immune-related toxicities, characterize the patients that develop them and ultimately work to manage toxicity without abrogating anti-tumor efficacy. In addition to the study of immune-related toxicities, she is also invested in evaluating novel combination strategies to overcome resistance to immune checkpoint inhibitors. During the COVID-19 (CD-19) pandemic she has expanded her research to focus on C19-related outcomes in a cancer population and to understand how the pandemic has impacted the delivery of care in an oncologic practice. Dr. Mooradian graduated from the Boston University School of Medicine and then went on to medical residency at Beth Israel Deaconess Medical Center in Boston, MA. Prior to joining the Massachusetts General Hospital (MGH) Cancer Center faculty, she completed her hematology/oncology fellowship at the MGH/Dana Farber Cancer Center.

Brought to you by